{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T05:05:16Z","timestamp":1782882316624,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Zhejiang Provincial National Science Foundation","award":["LY21H160007"],"award-info":[{"award-number":["LY21H160007"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16043-w","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T12:36:03Z","timestamp":1776774963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of Neutrophil-to-Lymphocyte Ratio (NLR) in patients with Leptomeningeal Metastasis (LM) from solid tumors"],"prefix":"10.1186","volume":"26","author":[{"given":"Nanyang","family":"Tong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunlin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"16043_CR1","first-page":"579","volume":"19","author":"JB Posner","year":"1978","unstructured":"Posner JB, Chernik NL. Intracranial metastases from systemic cancer. Adv Neurol. 1978;19:579\u201392.","journal-title":"Adv Neurol"},{"key":"16043_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1136\/pgmj.56.653.149","volume":"56","author":"R Boyle","year":"1980","unstructured":"Boyle R, Thomas M, Adams JH. Diffuse involvement of the leptomeninges by tumour\u2013a clinical and pathological study of 63 cases. Postgrad Med J. 1980;56:149\u201358.","journal-title":"Postgrad Med J"},{"key":"16043_CR3","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1212\/WNL.0000000000000455","volume":"82","author":"RL Glover","year":"2014","unstructured":"Glover RL, Brook AL, Welch MR. Teaching NeuroImages: leptomeningeal lung carcinoma. Neurology. 2014;82:e183\u2013184.","journal-title":"Neurology"},{"key":"16043_CR4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/1097-0142(19830101)51:1<154::AID-CNCR2820510130>3.0.CO;2-K","volume":"51","author":"CP Kokkoris","year":"1983","unstructured":"Kokkoris CP. Leptomeningeal carcinomatosis. How does cancer reach the pia-arachnoid? Cancer. 1983;51:154\u201360.","journal-title":"Cancer"},{"key":"16043_CR5","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41568-024-00700-y","volume":"24","author":"J Remsik","year":"2024","unstructured":"Remsik J, Boire A. The path to leptomeningeal metastasis. Nat Rev Cancer. 2024;24:448\u201360.","journal-title":"Nat Rev Cancer"},{"key":"16043_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jns.2004.05.008","volume":"223","author":"U Herrlinger","year":"2004","unstructured":"Herrlinger U, Forschler H, Kuker W, Meyermann R, Bamberg M, Dichgans J, Weller M. Leptomeningeal metastasis: survival and prognostic factors in 155 patients. J Neurol Sci. 2004;223:167\u201378.","journal-title":"J Neurol Sci"},{"key":"16043_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11060-007-9340-4","volume":"84","author":"H Rudnicka","year":"2007","unstructured":"Rudnicka H, Niwinska A, Murawska M. Breast cancer leptomeningeal metastasis\u2013the role of multimodality treatment. J Neurooncol. 2007;84:57\u201362.","journal-title":"J Neurooncol"},{"key":"16043_CR8","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1215\/15228517-2008-062","volume":"10","author":"L Harstad","year":"2008","unstructured":"Harstad L, Hess KR, Groves MD. Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. Neuro Oncol. 2008;10:1010\u20138.","journal-title":"Neuro Oncol"},{"key":"16043_CR9","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1093\/annonc\/mdq232","volume":"21","author":"H Gauthier","year":"2010","unstructured":"Gauthier H, Guilhaume MN, Bidard FC, Pierga JY, Girre V, Cottu PH, Laurence V, Livartowski A, Mignot L, Dieras V. Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol. 2010;21:2183\u20137.","journal-title":"Ann Oncol"},{"key":"16043_CR10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s11060-010-0524-y","volume":"104","author":"CR de Azevedo","year":"2011","unstructured":"de Azevedo CR, Cruz MR, Chinen LT, Peres SV, Peterlevitz MA, de Azevedo Pereira AE, Fanelli MF, Gimenes DL. Meningeal carcinomatosis in breast cancer: prognostic factors and outcome. J Neurooncol. 2011;104:565\u201372.","journal-title":"J Neurooncol"},{"key":"16043_CR11","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s10549-011-1682-0","volume":"129","author":"S Lee","year":"2011","unstructured":"Lee S, Ahn HK, Park YH, Nam DH, Lee JI, Park W, Choi DH, Huh SJ, Park KT, Ahn JS, Im YH. Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations. Breast Cancer Res Treat. 2011;129:809\u201317.","journal-title":"Breast Cancer Res Treat"},{"key":"16043_CR12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/JTO.0b013e318287c943","volume":"8","author":"HS Gwak","year":"2013","unstructured":"Gwak HS, Joo J, Kim S, Yoo H, Shin SH, Han JY, Kim HT, Lee JS, Lee SH. Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer. J Thorac Oncol. 2013;8:599\u2013605.","journal-title":"J Thorac Oncol"},{"key":"16043_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11060-013-1092-8","volume":"113","author":"E Le Rhun","year":"2013","unstructured":"Le Rhun E, Taillibert S, Zairi F, Kotecki N, Devos P, Mailliez A, Servent V, Vanlemmens L, Vennin P, Boulanger T, et al. A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer. J Neurooncol. 2013;113:83\u201392.","journal-title":"J Neurooncol"},{"key":"16043_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11060-013-1175-6","volume":"114","author":"S Yust-Katz","year":"2013","unstructured":"Yust-Katz S, Garciarena P, Liu D, Yuan Y, Ibrahim N, Yerushalmi R, Penas-Prado M, Groves MD. Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis. J Neurooncol. 2013;114:229\u201335.","journal-title":"J Neurooncol"},{"key":"16043_CR15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jocn.2015.11.012","volume":"27","author":"JV Brower","year":"2016","unstructured":"Brower JV, Saha S, Rosenberg SA, Hullett CR, Ian Robins H. Management of leptomeningeal metastases: Prognostic factors and associated outcomes. J Clin Neurosci. 2016;27:130\u20137.","journal-title":"J Clin Neurosci"},{"key":"16043_CR16","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/annonc\/mdw134","volume":"27","author":"MH Geukes Foppen","year":"2016","unstructured":"Geukes Foppen MH, Brandsma D, Blank CU, van Thienen JV, Haanen JB, Boogerd W. Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma. Ann Oncol. 2016;27:1138\u201342.","journal-title":"Ann Oncol"},{"key":"16043_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clbc.2016.07.002","volume":"17","author":"A Morikawa","year":"2017","unstructured":"Morikawa A, Jordan L, Rozner R, Patil S, Boire A, Pentsova E, Seidman AD. Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis. Clin Breast Cancer. 2017;17:23\u20138.","journal-title":"Clin Breast Cancer"},{"key":"16043_CR18","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1093\/neuonc\/noz208","volume":"22","author":"KS Nevel","year":"2020","unstructured":"Nevel KS, DiStefano N, Lin X, Skakodub A, Ogilvie SQ, Reiner AS, Pentsova E, Boire A. A retrospective, quantitative assessment of disease burden in patients with leptomeningeal metastases from non-small-cell lung cancer. Neuro Oncol. 2020;22:675\u201383.","journal-title":"Neuro Oncol"},{"key":"16043_CR19","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541\u201350.","journal-title":"Nat Med"},{"key":"16043_CR20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348:74\u201380.","journal-title":"Science"},{"key":"16043_CR21","unstructured":"Shrihari T G. Innate and adaptive immune cells in Tumor microenvironment. Gulf J Oncolog 2021, 1:77\u201381. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/39539368."},{"key":"16043_CR22","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/imr.12444","volume":"273","author":"LW Treffers","year":"2016","unstructured":"Treffers LW, Hiemstra IH, Kuijpers TW, van den Berg TK, Matlung HL. Neutrophils in cancer. Immunol Rev. 2016;273:312\u201328.","journal-title":"Immunol Rev"},{"key":"16043_CR23","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.lungcan.2017.07.024","volume":"111","author":"S Diem","year":"2017","unstructured":"Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton AJ, Fruh M. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176\u201381.","journal-title":"Lung Cancer"},{"key":"16043_CR24","doi-asserted-by":"publisher","first-page":"175883592094237","DOI":"10.1177\/1758835920942378","volume":"12","author":"A Galvano","year":"2020","unstructured":"Galvano A, Peri M, Guarini AA, Castiglia M, Grassadonia A, De Tursi M, Irtelli L, Rizzo S, Bertani A, Gristina V, et al. Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score. Ther Adv Med Oncol. 2020;12:1758835920942378.","journal-title":"Ther Adv Med Oncol"},{"key":"16043_CR25","doi-asserted-by":"publisher","unstructured":"Grassadonia A, Graziano V, Iezzi L, Vici P, Barba M, Pizzuti L, Cicero G, Krasniqi E, Mazzotta M, Marinelli D et al. Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting. Cells. 2021;10(7):1685. https:\/\/doi.org\/10.3390\/cells1007168.\u00a0Published 2021 Jul 3.","DOI":"10.3390\/cells1007168"},{"key":"16043_CR26","doi-asserted-by":"publisher","unstructured":"Fang T, Wang Y, Yin X, Zhai Z, Zhang Y, Yang Y, You Q, Li Z, Ma Y, Li C et al. Diagnostic Sensitivity of NLR and PLR in Early Diagnosis of Gastric Cancer. J Immunol Res. 2020;2020:9146042. https:\/\/doi.org\/10.1155\/2020\/9146042.","DOI":"10.1155\/2020\/9146042"},{"key":"16043_CR27","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12935-022-02704-w","volume":"22","author":"F Wang","year":"2022","unstructured":"Wang F, Chen L, Wang Z, Xu Q, Huang H, Wang H, Li X, Yu M, Chen J, Lin F, et al. Prognostic value of the modified systemic inflammation score in non-small-cell lung cancer with brain metastasis. Cancer Cell Int. 2022;22:320.","journal-title":"Cancer Cell Int"},{"key":"16043_CR28","doi-asserted-by":"publisher","unstructured":"Zhang D, Zeng H, Pan Y, Zhao Y, Wang X, Chen J, Wang J, Zhang Y, Zhou Z, Xu L et al. Liver Tumor Markers, HALP Score, and NLR: Simple, Cost-Effective, Easily Accessible Indexes for Predicting Prognosis in ICC Patients after Surgery. J Pers Med. 2022;12(12):2041.\u00a0https:\/\/doi.org\/10.3390\/jpm12122041.\u00a0Published 2022 Dec 9.","DOI":"10.3390\/jpm12122041"},{"key":"16043_CR29","doi-asserted-by":"publisher","first-page":"e7132","DOI":"10.7717\/peerj.7132","volume":"7","author":"D Wang","year":"2019","unstructured":"Wang D, Bai N, Hu X, OuYang XW, Yao L, Tao Y, Wang Z. Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC. PeerJ. 2019;7:e7132.","journal-title":"PeerJ"},{"key":"16043_CR30","doi-asserted-by":"publisher","first-page":"1492358","DOI":"10.3389\/fnut.2024.1492358","volume":"11","author":"S Qi","year":"2024","unstructured":"Qi S, Ma Z, Shen L, Wang J, Zhou L, Tian B, Liu C, Chen K, Cheng W. Application of preoperative NLR-based prognostic model in predicting prognosis of intrahepatic cholangiocarcinoma following radical surgery. Front Nutr. 2024;11:1492358.","journal-title":"Front Nutr"},{"key":"16043_CR31","doi-asserted-by":"publisher","first-page":"101624","DOI":"10.1016\/j.esmoop.2023.101624","volume":"8","author":"E Le Rhun","year":"2023","unstructured":"Le Rhun E, Weller M, van den Bent M, Brandsma D, Furtner J, Ruda R, Schadendorf D, Seoane J, Tonn JC, Wesseling P, et al. Leptomeningeal metastasis from solid tumours: EANO-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. ESMO Open. 2023;8:101624.","journal-title":"ESMO Open"},{"key":"16043_CR32","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1524-4741.2012.01228.x","volume":"18","author":"F Lara-Medina","year":"2012","unstructured":"Lara-Medina F, Crismatt A, Villarreal-Garza C, Alvarado-Miranda A, Flores-Hernandez L, Gonzalez-Pinedo M, Gamboa-Vignolle C, Ruiz-Gonzalez JD, Arrieta O. Clinical features and prognostic factors in patients with carcinomatous meningitis secondary to breast cancer. Breast J. 2012;18:233\u201341.","journal-title":"Breast J"},{"key":"16043_CR33","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1179\/1973947812Y.0000000034","volume":"24","author":"I Meattini","year":"2012","unstructured":"Meattini I, Livi L, Saieva C, Franceschini D, Marrazzo L, Greto D, Scotti V, Scoccianti S, Paiar F, Bordi L, et al. Prognostic factors and clinical features in patients with leptominengeal metastases from breast cancer: a single center experience. J Chemother. 2012;24:279\u201384.","journal-title":"J Chemother"},{"key":"16043_CR34","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/JTO.0b013e3182398e4f","volume":"7","author":"PG Morris","year":"2012","unstructured":"Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM, Omuro AM. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol. 2012;7:382\u20135.","journal-title":"J Thorac Oncol"},{"key":"16043_CR35","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1634\/theoncologist.2014-0199","volume":"19","author":"HS Gwak","year":"2014","unstructured":"Gwak HS, Joo J, Shin SH, Yoo H, Han JY, Kim HT, Yun T, Ro J, Lee JS, Lee SH. Ventriculolumbar perfusion chemotherapy with methotrexate for treating leptomeningeal carcinomatosis: a Phase II Study. Oncologist. 2014;19:1044\u20135.","journal-title":"Oncologist"},{"key":"16043_CR36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.lungcan.2015.05.023","volume":"89","author":"JL Kuiper","year":"2015","unstructured":"Kuiper JL, Hendriks LE, van der Wekken AJ, de Langen AJ, Bahce I, Thunnissen E, Heideman DA, Berk Y, Buijs EJ, Speel EJ, et al. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis. Lung Cancer. 2015;89:255\u201361.","journal-title":"Lung Cancer"},{"key":"16043_CR37","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3346\/jkms.2014.29.8.1094","volume":"29","author":"J Kwon","year":"2014","unstructured":"Kwon J, Chie EK, Kim K, Kim HJ, Wu HG, Kim IH, Oh DY, Lee SH, Kim DW, Im SA, et al. Impact of multimodality approach for patients with leptomeningeal metastases from solid tumors. J Korean Med Sci. 2014;29:1094\u2013101.","journal-title":"J Korean Med Sci"},{"key":"16043_CR38","doi-asserted-by":"publisher","first-page":"e000283","DOI":"10.1136\/esmoopen-2017-000283","volume":"3","author":"IC Glitza","year":"2018","unstructured":"Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL Jr., Bernatchez C, Diab A, Woodman SE, Yee C, Amaria RN, Patel SP, et al. Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open. 2018;3:e000283.","journal-title":"ESMO Open"},{"key":"16043_CR39","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/neuonc\/now197","volume":"19","author":"M Chamberlain","year":"2017","unstructured":"Chamberlain M, Junck L, Brandsma D, Soffietti R, Ruda R, Raizer J, Boogerd W, Taillibert S, Groves MD, Le Rhun E, et al. Leptomeningeal metastases: a RANO proposal for response criteria. Neuro Oncol. 2017;19:484\u201392.","journal-title":"Neuro Oncol"},{"key":"16043_CR40","doi-asserted-by":"publisher","unstructured":"Ozkan O, Peker P, Gecgel A, Goker E. Prognostic Value of Preoperative Lymphocyte-to-Monocyte Ratio in Patients with Recurrent Colorectal Cancer. Med (Kaunas). 2025;61(4):707. https:\/\/doi.org\/10.3390\/medicina61040707.\u00a0Published 2025 Apr 11.","DOI":"10.3390\/medicina61040707"},{"key":"16043_CR41","doi-asserted-by":"publisher","first-page":"114613","DOI":"10.1016\/j.celrep.2024.114613","volume":"43","author":"YS Li","year":"2024","unstructured":"Li YS, Lai WP, Yin K, Zheng MM, Tu HY, Guo WB, Li L, Lin SH, Wang Z, Zeng L, et al. Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLC. Cell Rep. 2024;43:114613.","journal-title":"Cell Rep"},{"key":"16043_CR42","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1093\/neuonc\/noae138","volume":"26","author":"JWT van der Wel","year":"2024","unstructured":"van der Wel JWT, Boelens MC, Jebbink M, Smulders SA, Maas KW, Luitse MJA, Compter A, Boltjes RPB, Sol N, Monkhorst K, et al. Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study. Neuro Oncol. 2024;26:2316\u201327.","journal-title":"Neuro Oncol"},{"key":"16043_CR43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.expneurol.2015.07.027","volume":"273","author":"R Spector","year":"2015","unstructured":"Spector R, Robert Snodgrass S, Johanson CE. A balanced view of the cerebrospinal fluid composition and functions: Focus on adult humans. Exp Neurol. 2015;273:57\u201368.","journal-title":"Exp Neurol"},{"key":"16043_CR44","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.ccell.2024.05.004","volume":"42","author":"CS McGinnis","year":"2024","unstructured":"McGinnis CS, Miao Z, Superville D, Yao W, Goga A, Reticker-Flynn NE, Winkler J, Satpathy AT. The temporal progression of lung immune remodeling during breast cancer metastasis. Cancer Cell. 2024;42:1018\u2013e10311016.","journal-title":"Cancer Cell"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16043-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16043-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16043-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T04:00:11Z","timestamp":1782878411000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16043-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16043"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16043-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"5 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated: Updated the affiliation from \"Department of Neurosurgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.\" to Department of Neurosurgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedural aspects of this investigation were conducted in accordance with the 2013 revision of the Declaration of Helsinki. The study was approved by the Ethics Committee of Zhejiang Cancer Hospital, with an approval number of IIT-2025-206, which waived the requirement for informed consent because the study was retrospective and relied solely on fully anonymised data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All co-authors have read the final version of the manuscript, endorsed its content, and approved its submission to BMC Cancer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"715"}}